On Air Now

Current Show

Jerry Bader   9:00 AM - 11:00 AM

Call The Jerry Bader Show at 1-888-455-1360

Show Info »

Upcoming Shows

Program Schedule »

Listen

Listen Live Now » 550 AM Wausau, WI 99.9 FM Stevens Point, WI

Weather

Current Conditions(Wausau,WI 54403)

More Weather »
61° Feels Like: 61°
Wind: SW 7 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Today

AM Thunderstorms 75°

Tonight

Clear 53°

Tomorrow

Mostly Sunny 79°

Alerts

Shire boosts rare diseases business by buying Premacure

LONDON (Reuters) - Shire increased its investment in rare diseases on Tuesday by acquiring privately held Swedish biotech firm Premacure, which is developing a drug for a potentially blinding eye disorder in premature babies.

Britain's third biggest drugmaker did not reveal how much it was paying for the Uppsala-based business but said it would pay a sum upfront followed by contingent payments based on clinical development and commercial success.

The acquisition takes Shire into the new area of neonatology - the treatment of sick or premature newborn infants - and expands its already substantial presence in rare diseases.

Treating diseases that affect only a small number of patients is a growing focus for many drug companies given the high prices that can be achieved.

Premacure, which was launched in 2006, has an experimental protein replacement medicine in mid-stage Phase II clinical development for the prevention of retinopathy of prematurity (ROP).

Normal full-term babies produce enough growth factors on their own to prevent diseases like ROP. But those born before 31 weeks may lack chemicals such as insulin-like growth factor 1 (IGF-1), which can result in life-long complications like ROP.

Shire said its human genetic therapies unit would continue with the Phase II study, the primary goal of which is to restore the IGF-1 levels in premature infants to those found in babies born at full term.

(Reporting by Ben Hirschler; Editing by Greg Mahlich)

Comments